Barclays PLC Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Barclays PLC acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 54,886 shares of the company’s stock, valued at approximately $731,000. Barclays PLC owned 0.21% of Eton Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ETON. Cannell Capital LLC bought a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $5,079,000. Geode Capital Management LLC raised its holdings in shares of Eton Pharmaceuticals by 13.5% during the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after buying an additional 32,365 shares during the last quarter. Aristides Capital LLC boosted its position in shares of Eton Pharmaceuticals by 20.8% during the fourth quarter. Aristides Capital LLC now owns 241,587 shares of the company’s stock worth $3,218,000 after buying an additional 41,587 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Eton Pharmaceuticals by 230.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock worth $2,862,000 after buying an additional 149,864 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Eton Pharmaceuticals by 131.5% in the 4th quarter. Renaissance Technologies LLC now owns 193,100 shares of the company’s stock valued at $2,572,000 after acquiring an additional 109,700 shares during the period. Institutional investors own 27.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ETON shares. B. Riley reissued a “buy” rating and issued a $24.00 price target (up previously from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, March 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $16.60 on Wednesday. The firm has a market cap of $445.07 million, a price-to-earnings ratio of -75.44 and a beta of 1.22. Eton Pharmaceuticals, Inc. has a 1 year low of $3.18 and a 1 year high of $18.41. The firm’s 50 day moving average price is $14.34 and its two-hundred day moving average price is $13.41.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02). The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, equities analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.